PTU-029 Are extra-pancreatic malignancies more prevalent in patients with intraductal papillary mucinous neoplasm of the pancreas?. (8th June 2018)

• Record Type: Journal Article
• Authors: Tabone, Trevor; Cortis, Kelvin; Azzopardi, Neville
• Is Part Of: Gut. Volume 67(2018)Supplement 1
• Page Start: A158
• Page End: A159
• Publication Date: 2018-06-08
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-BSGAbstracts.314
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: The association between the presence of an intraductal papillary mucinous neoplasm (IPMN) of the pancreas and the prevalence of extra-pancreatic malignancies (EPM) remains unclear. This is important with regards to determining suitable follow-up plans for IPMN patients. This single-centre, retrospective study aims to determine whether the prevalence of EPM is higher in IPMN patients as compared to the general Maltese population. Methods: A cohort of 175 patients with an incidental radiological diagnosis of IPMN on magnetic resonance imaging between 2010 and 2017 were recruited from a single, main centre in Malta. The prevalence of a previous history or synchronous diagnosis of EPM was recorded by reviewing electronic histopathology results of biopsies or resection specimens. EPM was defined as per ICD-10 (International Statistical Classification of Diseases and Related Health Problems) C00–80, thus excluding non-melanoma skin cancer and haematological malignancies. All EPMs were based on a tissue diagnosis. The prevalence of EPM was calculated and statistically compared with the lifetime prevalence of developing EPM (ICD-10, C00-C80) in the general Maltese population. Data regarding population demographics was obtained from the National Statistics Office and the National Cancer Platform. Results: 36 out of a total of 175 IPMN patients were found to have an EPM resulting in a prevalence of 20.57%. The commonest malignancies were breast 30.6% (n=11), colorectal 25.0% (n=9), and renal cell carcinoma 11.1% (n=4) respectively. The calculated lifetime prevalence (risk) of developing an EPM (Adjusted for Multiple Primaries – AMP method) in the general Maltese population is 19.5% (1 in 5). This was not found to be statistically significantly different when compared to the IPMN patient cohort (p=0.86). Conclusions: A previous history or synchronous histological diagnosis of EPM was not shown to be more prevalent in patients diagnosed with an IPMN of the pancreas, as compared to the general Maltese population. Given these findings, there is currently no rationale for undergoing further thorough investigations for an EPM in IPMN patients. The need for prospective, long-term follow-up studies in such patients is paramount to establish incidence rates for EPMs following an IPMN diagnosis.